ImmunityBio Revenue
Biotechnology Research • 
San Diego, California, United States • 501-1000 Employees
ImmunityBio revenue & valuation
| Annual revenue | $31,300,000 |
| Revenue per employee | $54,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $100,000,000 |
| Total funding | $535,000,000 |
Company overview
| Headquarters | 3530 John Hopkins Ct, San Diego, CA 92121, US |
| Phone number | +18446965235 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Clinical Trials, Manufacturing, Cancer, Oncology, Immunotherapy, Cell Therapy, Infectious Diseases, Yeast, Vaccines, Vaccine, Fusion Proteins, Covid-19, Natural Killer, T Cell |
| Employees | 501-1000 |
| Socials |
ImmunityBio Email Formats
ImmunityBio uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@immunitybio.com), used 82.8% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@immunitybio.com | 82.8% |
{first initial}.{last name} | j.doe@immunitybio.com | 15.3% |
{first name}{last name} | johndoe@immunitybio.com | 1.1% |
About ImmunityBio
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman
Employees by Management Level
Total employees: 501-1000
Seniority
Employees
Employees by Department
ImmunityBio has 368 employees across 19 departments.
Departments
Number of employees
Funding Data
Explore ImmunityBio's funding history, including investment rounds, total capital raised, and key backers.
ImmunityBio Tech Stack
Discover the technologies and tools that power ImmunityBio's digital infrastructure, from frameworks to analytics platforms.
Video players
Security
Recruitment & staffing
JavaScript libraries
Video players
JavaScript libraries
Maps
JavaScript libraries
JavaScript libraries
CDN
JavaScript libraries
Analytics
United Kingdom
Denmark
Switzerland
Germany
Frequently asked questions
Key Contact at ImmunityBio
4.8
40,000 users
